Lumifil L-Kiss with Lidocaine is a cross-linked hyaluronic acid dermal filler developed for practitioners requiring structure and definition in lip treatments. Positioned within the Lumifil range as a higher-viscosity option, it is commonly selected where shape control and projection are clinically important. The formulation contains 20mg/ml sodium hyaluronate combined with 0.3% lidocaine. This concentration supports volumisation while maintaining gel integrity within mobile tissue such as the lips. In aesthetic practice, lip treatments frequently require a balance between softness and structural support. Products with insufficient viscosity may compromise border definition, while excessively firm gels may limit natural movement. L-Kiss is positioned to provide a structured yet workable consistency suitable for contour refinement and volumetric support. Clinically, the product is typically used for vermillion body volume, vermillion border definition and lip contour shaping. Depending on practitioner assessment and technique, it may also be considered for selected facial areas where moderate structural support is required, such as the nasolabial folds, chin or cheeks. Product selection should always reflect tissue characteristics, patient expectations and anatomical considerations. Longevity is approximately 9 to 12 months. Duration varies according to injection depth, product placement, metabolic rate and treatment area. As with all dermal fillers, outcomes are dependent on practitioner technique and appropriate patient selection. How It Works Cross-linked hyaluronic acid is placed within the target tissue to provide localised volume and contour support. The cross-linking process increases gel stability, allowing the product to maintain structure within the treated area. The higher viscosity supports placement control and shape definition. Lidocaine is incorporated to reduce injection discomfort during treatment. Key Benefits • Designed for lip volume and contour definition • 20mg/ml cross-linked sodium hyaluronate • Higher-viscosity gel for structural support • Includes 0.3% lidocaine • Typical longevity guidance of 9 to 12 months, patient dependent